Effects of demethylating agent 5-aza-2′-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines

Oral Oncology

Volumn 40, Issue 6, 2004, Pages 597-603

  Murakami, Jun ^a   Asaumi, Jun Ichi ^a   Maki, Yuu ^a   Tsujigiwa, Hidetsugu ^a   Kuroda, Masahiro ^a   Nagai, Noriyuki ^a   Yanagi, Yoshinobu ^a   Inoue, Tetsuyoshi ^a   Kawasaki, Shoji ^a   Tanaka, Noriaki ^a   Matsubara, Nagahide ^a   Kishi, Kanji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

5 Aza 2 deoxycytidine; FR901228; Maspin; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FR 901228; HISTONE DEACETYLASE INHIBITOR; MASPIN; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METHYLATION; MOUTH CANCER; PRIORITY JOURNAL; PROMOTER REGION;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; DEPSIPEPTIDES; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MOUTH NEOPLASMS; PEPTIDES, CYCLIC; PROTEINS; RNA, MESSENGER; SERPINS; TRANSCRIPTION, GENETIC;

EID: 11144356238     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2003.12.008     Document Type: Article

References (33)

1. Zou Z., Anisowicz A., Hendrix M.J.C., Thor A., Neveu M., Sheng S.et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science (Washington DC). 263:1994;526-529.
2. Futscher B.W., Oshiro M.M., Wnzniak R.J., Holtan N., Hanigan C.L., Duan H.et al. Role for DNA methylation in the control of cell type-specific maspin expression. Nat. Genet. 31(2):2002;175-179.
3. Hendrix M.J. De-mystifying the mechanism(s) of maspin. Nat. Med. 6:2000;374-376.
4. Sheng S., Pemberton P.A., Sager R. Production, purification, and characterization of recombinant maspin proteins. J. Biol. Chem. 269:1994;30988-30993.
5. Sager R., Sheng S., Anisowicz A., Sotiropoulou G., Zou Z., Stenman G.et al. RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harbor Symp. Quant. Biol. 59:1994;537-546.
6. Zhang M., Magit D., Sager R. Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc. Natl. Acad. Sci. USA. 94:1997;5673-5678.
7. Seftor R.E., Seftor E.A., Sheng S., Pemberton P.A., Sager R., Hendrix M.J. Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res. 58:1998;5681-5685.
8. Pemberton P.A., Wong D.T., Gibson H.L., Kiefer M.C., Fitzpatrick P.A., Sager R.et al. The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin. J. Biol. Chem. 270:1995;15832-15837.
9. Sheng S., Carey J., Seftor E., Dias L., Hendrix M.J.C., Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA. 93:1996;11669-11674.
10. Zhang M., Volpert O., Shi Y.H., Bouck N. Maspin is an angiogenesis inhibitor. Nat. Med. 6:2000;196-199.
11. Zhang M., Shi Y., Magit D., Furth P.A., Sager R. Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene. 19:2000;6053-6058.
12. Zhang M., Sheng S., Mass N., Sager R. mMaspin, the mouse homolog of a human tumor suppressor gene, inhibits tumor invasion and motility. Mol. Med. 3:1997;49-59.
13. Sager R., Sheng S., Pemberton P., Hendrix M.J.C. Maspin, a tumor suppressing serpin. Adv. Exp. Med. Biol. 425:1997;77-88.
14. Domann F.E., Rice J.C., Hendrix M.J.C., Futscher B.W. Epigenetic silencing of maspin gene expression in human breast cancers. Int. J. Cancer. 85(6):2000;805-810.
15. Zhang M., Mass N., Magit D., Sager R. Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene Maspin. Cell Growth Differ. 8:1997;179-186.
16. Li J.J., Colburn N.H., Oberley L.W. Maspin gene expression in tumor suppression induced by overexpressing manganese-containing superoxide dismutase cDNA in human breast cancer cells. Carcinogenesis. 19(5):1998;833-839.
17. Biliran H. Jr., Sheng S. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res. 61(24):2001;8676-8682.
18. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., Kouzarides T. DNA methyltransferase dnmt1 associates with histone deacetylase activity. Nat. Genet. 24:2000;88-91.
19. Rountree M.R., Bachman K.E., Baylin S.B. DNMT1 binds HDAC2 and a new co-repressor DMAP1 to for a complex at replication foci. Nat. Genet. 25:2000;269-277.
20. Kondo Y., Shen L.L., Issa J.P. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol. 23(1):2003;206-215.
21. Milutinovic S., Knox J.D., Szyf M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21 (WAF1/CIP1/sdi1). J. Biol. Chem. 275:2000;6353-6359.
22. Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X.et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 409:2001;207-211.
23. Archer S.Y., Meng S., Shei A., Hodin R.A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA. 95(12):1998;6791-6796.
24. Nakano K., Mizuno T., Sowa Y., Orita T., Yoshino T., Okuyama Y.et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem. 272(35):1997;22199- 22206.
25. Janson W., Brandner G., Siegel J. Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene. 15(12):1997;1395-1406.
26. Heruth D.P., Zirnstein G.W., Bradley J.F., Rothberg P.G. Sodium butyrate causes an increase in the block to transcriptional elongation in the c-myc gene in SW837 rectal carcinoma cells. J. Biol. Chem. 268:1993;20466-20472.
27. Buckley A.R., Leff M.A., Buckley D.J., Magnuson N.S., De Jong G., Gout P.W. Alterations in pim-1 and c-myc expression associated with butyrate-induced growth factor dependence in autonomous rat NB2 lymphoma cells. Cell Growth Differ. 7:1996;1713-1721.
28. Mandal M., Kumar R. Bcl-2 expression regulates sodium butyrate- induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ. 7:1996;311-318.
29. Hague A., Diaz G.D., Hicks D.J., Krajewski S., Reed J.C., Paraskeva C. Bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however, overexpression of bcl-2 does not protect against bak-mediated apoptosis. Int. J. Cancer. 72:1997;898-905.
30. Butler L.M., Zhou X., Xu W.S., Scher H.I., Rifkind R.A., Marks P.A.et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA. 99(18):2002;11700-11705.
31. Oikawa T., Onozawa C., Inose M., Sasaki M. Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo. Biol. Pharm. Bull. 18(9):1995;1305-1307.
32. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W.et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7(4):2001;437-443.
33. Xia W., Lau Y.K., Hu M.C., Li L., Johnston D.A., Sheng S.et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene. 19:2000;2398-2403.